Prosecution Insights
Last updated: April 19, 2026
Application No. 16/938,475

ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH

Final Rejection §102§DP
Filed
Jul 24, 2020
Examiner
ROZOF, TIMOTHY R
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Xeniopro GmbH
OA Round
12 (Final)
73%
Grant Probability
Favorable
13-14
OA Rounds
2y 2m
To Grant
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allow Rate
690 granted / 951 resolved
+12.6% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
32 currently pending
Career history
983
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
20.1%
-19.9% vs TC avg
§102
34.4%
-5.6% vs TC avg
§112
23.5%
-16.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 951 resolved cases

Office Action

§102 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This is a response to Applicant’s communication filed on November 10, 2025. Application No. 16/938,475, filed July 24, 2020, is Divisional of U.S. Nonprovisional Application No. 16/085,372, filed September 14, 2018, which is a 371 of PCT/EP2017/056461, filed March 17, 2017, and claims foreign priority to European Patent Office application No. (EPO) 16160988.8, filed March 17, 2016. In an amendment filed October 23, 2020, Applicant added claims 21-24. In an amendment filed March 23, 2021, Applicant cancelled claims 1-17, and 21; and added claims 25-35. In an amendment filed April 8, 2022, Applicant canceled claim 29 and added claims 36-39. In an amendment filed December 8, 2022, Applicant added claims 40 and 41. In an amendment filed July 17, 2023, Applicant added claims 42 and 43. In an amendment filed July 11, 2024, Applicant added new claims 44-50. In an amendment filed November 10, 2025, Applicant added new claims 51 and 52. Applicant’s elections without traverse of the invention of Group II and compound V150 as the elected compound species, in the reply filed on October 23, 2020, are acknowledged. Claim 43-49 are currently withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention. Claims 28, 30-32, 35, 37, 42, and 50 are currently withdrawn from further consid2734eration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species. Claims 18-20, 22-27, 33, 34, 36, 38-41, 51 and 52 are examined below Rejections Withdrawn The rejection of claims 18-20, 22, 33, and 36 under 35 U.S.C. 102(a)(1) as being anticipated by Hara et al., WO93/24442 A1, is withdrawn in view of Applicant’s November 10, 2025, Amendment & Remarks. The rejection of claims 18-20, 22, 33, 36, 38 and 41 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Stivers et al., US2008/0020973 A1, is withdrawn in view of Applicant’s November 10, 2025, Amendment & Remarks. New Rejection Claim Rejections - 35 USC § 102(a)(1) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 18-20, 22, 33, 36, 38 and 41 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Pessel, Leopold, U.S. Patent No. 2,734,000. Pessel discloses the following compound and pharmaceutical composition (as broadly construed by the present invention) thereof: PNG media_image1.png 196 409 media_image1.png Greyscale See Pessel, U.S. ‘000 patent, Col. 3., Ln. 40, “Meta (para-tertiary amylphenoxy) benzoic acid”.) This compound reads on a compound of general formula (I), wherein formula (I), X is an unsubstituted phenylene ring; Y is O; R6 is -OH; R1 is -C(CH3)2C2H5; and R2-R5 is hydrogen. Rejections Maintained Provisional Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. The provisional rejections of claims 18-20, 22-27, 33, 34, 36, 38-41, and 51-52 on the ground(s) of nonstatutory double patenting as being unpatentable over: claims 1-26, 28, and 30-36 of copending Application No. 17/270,646; claims 1-36 of copending Application No. 17/270,652; claims 1-38 of copending Application No. 17/270,665; and claims 1-21 of copending Application No. 18/064,576, are maintained for reasons made of record. Applicant argues that these provisional rejections are traversed because (i) the provisional nonstatutory double patenting rejections are the only rejections remaining; and (ii) the instant application has an earlier patent term filing date than the co-pending applications. In this case, these provisional rejections are not the only rejections remaining in this application. See the 35 U.S.C. 102(a)(1) Rejections above. Secondly, application No. 18/964,576, has an earlier filing date than the present application of February 24, 2017. With respect to co-pending Applications Nos.: 17/270,646; 17/270,652; and 17/270,665, the rejections will be maintained until a proper response is filed. See MPEP 1490. VI. D, Two or More Copending Applications. These are provisional nonstatutory double patenting rejections because the patentably indistinct claims have not in fact been patented. However, with respect to application No. 18/064,576, a Notice of Allowance was issued on November 24, 2025. This rejection will no longer be provisional upon paying the issue fee. Conclusion No claims are allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached on Monday - Friday, 9:00 a.m. -5:00 p.m.. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached on (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Jul 24, 2020
Application Filed
Dec 18, 2020
Non-Final Rejection — §102, §DP
Mar 23, 2021
Response Filed
Jun 09, 2021
Final Rejection — §102, §DP
Jun 24, 2021
Final Rejection — §102, §DP
Jun 24, 2021
Applicant Interview (Telephonic)
Sep 14, 2021
Response after Non-Final Action
Oct 27, 2021
Request for Continued Examination
Nov 01, 2021
Response after Non-Final Action
Nov 03, 2021
Non-Final Rejection — §102, §DP
Apr 08, 2022
Response Filed
Jun 03, 2022
Final Rejection — §102, §DP
Dec 08, 2022
Request for Continued Examination
Dec 09, 2022
Response after Non-Final Action
Jan 10, 2023
Non-Final Rejection — §102, §DP
Jul 17, 2023
Response Filed
Sep 05, 2023
Final Rejection — §102, §DP
Mar 08, 2024
Request for Continued Examination
Mar 12, 2024
Response after Non-Final Action
Apr 05, 2024
Non-Final Rejection — §102, §DP
Jul 11, 2024
Response Filed
Sep 13, 2024
Final Rejection — §102, §DP
Dec 16, 2024
Request for Continued Examination
Dec 17, 2024
Response after Non-Final Action
Jan 09, 2025
Non-Final Rejection — §102, §DP
Apr 14, 2025
Response Filed
May 05, 2025
Non-Final Rejection — §102, §DP
Nov 10, 2025
Response Filed
Feb 05, 2026
Final Rejection — §102, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594259
TREATMENT REGIMEN FOR THE TREATMENT OF NEUROLOGICAL DISEASES OR CONDITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595264
HETEROCYCLIC GLP-1 AGONISTS
2y 5m to grant Granted Apr 07, 2026
Patent 12595255
HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES
2y 5m to grant Granted Apr 07, 2026
Patent 12577204
A SOLUTION OF TEMPO-DERIVATIVES FOR USE AS ELECTROLYTE IN REDOX-FLOW CELLS
2y 5m to grant Granted Mar 17, 2026
Patent 12577205
HYDROGENATION OF IMINES BY PALLADIUM BASED CATALYST
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

13-14
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+24.0%)
2y 2m
Median Time to Grant
High
PTA Risk
Based on 951 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month